buy belviq lorcaserin 10 mg
buy belviq lorcaserin 10 mg , works by controlling appetite – specifically by activating brain receptors for serotonin, a neurotransmitter that triggers feelings of satiety and satisfaction. Belviq is used together with diet and exercise to treat obesity.
buy belviq lorcaserin 10 mg is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes).
The drug, on the other hand, can help regulate these responses and therefore allow patients to control their hunger, cravings and portion sizes. Patients who take Lorcaserin report having less cravings and becoming full much faster, which helps them lose weight.
buy belviq lorcaserin 10 mg is an orally administered medication that promotes weight loss. It is used with diet and exercise in overweight adults with a weight-related medical problem or obese adults to lose weight and keep it off.
buy belviq lorcaserin 10 mg is a serotonin 2C (5-HT2C) receptor agonist. Although the exact mechanism of action is not known, lorcaserin is thought to selectively stimulate 5-HT2C receptors in the hypothalamus, the area of the brain known to play a major role in regulating hunger and food intake. By activating these receptors, lorcaserin may decrease food consumption by decreasing appetite and making a person feel full even after eating less food than usual.
buy belviq lorcaserin 10 mg was approved by the FDA in June, 2012. Use and distribution of lorcaserin is under strict control by the federal government as it has a potential for abuse and drug dependence. As such, lorcaserin is classified as a schedule IV controlled substance.
The recommended dose of lorcaserin is 10 mg administered by mouth twice a day. buy belviq lorcaserin 10 mg may be taken without regard to meals. Lorcaserin should be discontinued in patients who fail to achieve at least a 5% weight loss by week 12 since these patients are not likely to experience meaningful weight loss with continued treatment.